Made Scientific Inc, a US-based clinical- and commercial-stage cell therapy contract development and manufacturing organisation (CDMO), announced on Monday that it has entered into a manufacturing partnership with Cellergy Therapeutics Ltd, an Israeli biotechnology company developing first-in-class mitochondrial transplantation therapies.

The collaboration is aimed at advancing Cellergy's mitochondrial therapy CLG-001 toward first-in-human clinical studies.

Cellergy Therapeutics will leverage Made Scientific's GMP manufacturing capabilities to implement and scale Cellergy's proprietary mitochondrial isolation and purification process. This work will support the production of clinical-grade CLG-001 for upcoming trials under Israel's Ministry of Health compassionate-use framework and a Phase I clinical study with the US Food and Drug Administration (FDA).

CLG-001 is based on mitochondria purified from healthy donors and developed to restore cellular energy production, a novel therapeutic approach for conditions driven by mitochondrial dysfunction. These include metabolic disorders, neurodegenerative diseases, and age-related conditions.